Related Experiment Videos
Clinical effectiveness in first-episode patients.
Ruth I Ohlsen1, Mary S O'Toole, Rick G Purvis
1Section of Neurochemical Imaging, Institute of Psychiatry, De Crespigny Park, Box 54, London, SE5 8AF, UK. r.ohlsen@iop.kcl.ac.uk
Summary
Managing first-episode schizophrenia with atypical antipsychotics like quetiapine offers effective treatment. Early intervention is key for positive long-term outcomes in schizophrenia patients, balancing efficacy and tolerability.
Area of Science:
- Psychiatry
- Pharmacology
- Clinical Medicine
Background:
- First-episode schizophrenia presents unique management challenges.
- Early diagnosis and intervention are crucial for optimal patient outcomes.
- Newer atypical antipsychotics offer improved efficacy and tolerability for schizophrenia treatment.
Purpose of the Study:
- To review atypical antipsychotic data in first-episode schizophrenia patients.
- To present primary results from the F1RST study on quetiapine use.
- To evaluate quetiapine as a first-line treatment for schizophrenia.
Main Methods:
- Review of existing data on atypical antipsychotics.
- Analysis of primary results from the F1RST (Southwark first-onset psychosis) study.
- Assessment of quetiapine in specialist first-episode psychosis services.
Main Results:
- Atypical antipsychotics demonstrate efficacy and tolerability in first-episode schizophrenia.
- The F1RST study provides primary data on quetiapine's role.
- Quetiapine is a viable option for first-line schizophrenia management.
Conclusions:
- Atypical antipsychotics are suitable for the long-term management of schizophrenia from onset.
- Pharmacological treatments must address broader clinical effectiveness beyond symptom management.
- The F1RST study supports quetiapine's use in first-episode psychosis services.